These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37959304)

  • 1. Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease.
    Vernero M; Bezzio C; Ribaldone DG; Costa S; Scalvini D; Tribocco E; Manes G; Saibeni S
    J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
    Mocci G; Bodini G; Allegretta L; Cazzato AI; Chiri S; Aragona G; Perazzo P; Ferronato A; Graziani MG; Pagnini C; Zampaletta C; Graziosi C; Picchio M; Elisei W; Maconi G; Tursi A
    Biomedicines; 2022 Jul; 10(8):. PubMed ID: 35892698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
    Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A
    Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring.
    Wasserbauer M; Hlava S; Drabek J; Stovicek J; Minarikova P; Nedbalova L; Drasar T; Zadorova Z; Dolina J; Konecny S; Kojecky V; Kozeluhova J; Cernikova P; Pichlerova D; Kucerova B; Coufal S; Keil R
    PLoS One; 2022; 17(8):e0271299. PubMed ID: 35939424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
    Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B
    Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study.
    Lontai L; Gonczi L; Balogh F; Komlodi N; Resal T; Farkas K; Molnar T; Miheller P; Golovics PA; Schafer E; Szamosi T; Ilias A; Lakatos PL
    Dig Liver Dis; 2022 Dec; 54(12):1639-1645. PubMed ID: 35931624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
    Casanova MJ; Nantes Ó; Varela P; Vela-González M; Rivero M; Sierra-Gabarda O; Riestra S; Barreiro-de Acosta M; Martín-Rodríguez MDM; Gargallo-Puyuelo CJ; Reygosa C; Muñoz R; de la Filia-Molina IG; Núñez-Ortiz A; Kolle L; Calafat M; Huguet JM; Iglesias-Flores E; Martínez-Pérez TJ; Bosch O; Duque-Alcorta JM; Frago-Larramona S; Van Domselaar M; González-Cosano VM; Bujanda L; Rubio S; Mancebo A; Castro B; García-López S; de Francisco R; Nieto-García L; Laredo V; Gutiérrez-Casbas A; Mesonero F; Leo-Carnerero E; Cañete F; Ruiz L; Gros B; Del Moral-Martínez M; Rodríguez C; Chaparro M; Gisbert JP
    Aliment Pharmacol Ther; 2023 Jul; 58(1):60-70. PubMed ID: 37089065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
    Tursi A; Mocci G; Cuomo A; Ferronato A; Elisei W; Picchio M; Maconi G; Scaldaferri F; Papa A; ; Allegretta L; Aragona G; Bianco MA; Colucci R; Della Valle N; Faggiani R; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Pica R; Pranzo G; Rodino' S; Sacco R; Sebkova L; Scarcelli A; Serio M; Napolitano D; Pugliese D; Schiavoni E; Turchini L; Armuzzi A; Zampaletta C
    J Gastrointestin Liver Dis; 2022 Dec; 31(4):411-416. PubMed ID: 36535057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.
    Kumar P; Vuyyuru SK; Kante B; Kedia S; Sahu P; Ranjan MK; Mundhra S; Golla R; Kumar M; Virmani S; Gupta A; Yadav N; Makharia G; Ahuja V
    Indian J Gastroenterol; 2022 Oct; 41(5):446-455. PubMed ID: 36378484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
    Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
    J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study.
    Barberio B; Cingolani L; Canova C; Barbieri G; Sablich R; Urbano MT; Bertani L; Costa F; Bodini G; Demarzo MG; Ferronato A; Buda A; Melatti P; Massimi D; Savarino EV; Zingone F
    Therap Adv Gastroenterol; 2021; 14():17562848211031420. PubMed ID: 34349836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
    Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
    J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey.
    Sarlós P; Bikar A; Farkas N; Resál T; Szepes Z; Farkas K; Nagy F; Vincze Á; Miheller P; Molnár T
    Expert Opin Biol Ther; 2023; 23(8):827-832. PubMed ID: 37161387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 15. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
    Argollo M; Fiorino G; Gilardi D; Furfaro F; Roda G; Loy L; Allocca M; Peyrin-Biroulet L; Danese S
    Curr Pharm Des; 2019; 25(1):7-12. PubMed ID: 30864505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
    Blauvelt A; Lacour JP; Fowler JF; Weinberg JM; Gospodinov D; Schuck E; Jauch-Lembach J; Balfour A; Leonardi CL
    Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study.
    Kamat N; Kedia S; Ghoshal UC; Nehra A; Makharia G; Sood A; Midha V; Gupta V; Choudhuri G; Ahuja V
    Indian J Gastroenterol; 2019 Feb; 38(1):44-54. PubMed ID: 30645725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
    Macaluso FS; Cappello M; Busacca A; Fries W; Viola A; Costantino G; Magnano A; Vinci E; Ferracane C; Privitera AC; Piccillo G; Belluardo N; Giangreco E; Romano C; Citrano M; Graziano F; Garufi S; Bertolami C; Ventimiglia M; Scrivo B; Teresi G; Renna S; Rizzuto G; Casà A; Orlando A;
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3041-3049. PubMed ID: 34152636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.